SOURCE: Generex Biotechnology Corporation

December 05, 2006 07:00 ET

Generex Biotechnology Makes Poster Presentations of Clinical Data at International Diabetes Federation 19th World Diabetes Congress

TORONTO -- (MARKET WIRE) -- December 5, 2006 -- Generex Biotechnology Corporation (NASDAQ: GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it made two poster presentations of clinical data at the International Diabetes Federation 19th World Diabetes Congress (www.idf2006.org) in Cape Town, South Africa, December 3 - 7, 2006.

The first poster, entitled "Metformin Gum: An Alternative Method for Delivery of Biguanides," was authored by Drs. Jaime Guevara-Aguirre, David Saldarreaga, Marco Guevara-Aguirre, and Jeannette Saavedra of the Institute of Endocrinology IEMYR in Quito, Ecuador, and Dr. Gerald Bernstein, the Company's Vice-President - Medical Affairs.

The second poster, entitled "3-Month Interim Results (6-Month Study) on Safety and Efficacy of an Oral Insulin (Generex Oral-lyn™) Administered at Lunchtime in Juvenile Type-1 Diabetes Mellitus Subjects Maintained on Basal Glargine Insulin and Pre-Breakfast and Pre-Dinner Regular Insulin," was authored by Drs. Jaime Guevara-Aguirre, Marco Guevara-Aguirre and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR in Quito, Ecuador.

The World Diabetes Congress attracts the highest level of international expertise in diabetes, provides a platform for discussion of the latest scientific advances in the field, and offers practical information on diabetes care, advocacy and awareness.

The International Diabetes Federation (IDF) is the global advocate for the more than 200 million people with diabetes worldwide. It represents 197 Diabetes Associations in 157 countries. The mission of IDF is to promote diabetes care, prevention and a cure worldwide. IDF is a non-governmental organization in official relations with the World Health Organization (WHO).

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, oral insulin (Generex Oral-lyn™), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex website at www.generex.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Contact Information

  • Contacts:

    Shayne Gilliatt
    Generex Biotechnology Corporation
    Phone: (800) 391-6755
    or (416) 364-2551

    Andrew Hellman
    CEOcast, Inc.
    Phone: (212) 732-4300

    Dolores Naney
    Rubenstein Public Relations
    Phone: (212) 843-8018